Conference Track

Clinical Updates in HBV Treatment

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

GLOBE: 2-Year Results Confirm Superiority of Telbivudine Over Lamivudine in Patients With Chronic Hepatitis B
Continuation of Entecavir Treatment From 96 Weeks to 144 Weeks Associated With Increased Rates of Viral Suppression and ALT Normalization in Chronic HBV Patients
Entecavir More Effective Than Adefovir in Reducing HBV DNA Levels in Treatment-Naive HBeAg-Positive Patients From Day 10 to Week 24
Risk of Entecavir Resistance Remains Minimal in Treatment-Naive Patients, Increases Over Time Among Lamivudine-Refractory Patients
Adding Adefovir to Lamivudine More Effective at Suppressing HBV DNA Than Switching to Adefovir in Individuals With Lamivudine-Resistance and High Viral Load
Noninvasive FibroTest and FibroScan Tests Reliably Exclude Clinically Significant Fibrosis in Inactive HBV Carriers
Virologic Suppression in Patients Chronically Infected With HBeAg-Negative HBV Sustained for 2 Years Following 48 Weeks of Peginterferon Alfa-2a Treatment
HBV DNA Levels Following 4 Weeks of Treatment Predictive of Long-term Response to Lamivudine
Rapidity and Magnitude of HBV DNA Suppression With Antiviral Therapy Key Factor in T-Cell Reactivity for HBeAg-Positive Patients
Adding Adefovir to Lamivudine Less Likely to Result in Viral Breakthrough or Resistance Than Switch to Adefovir Monotherapy for Patients With Lamivudine-Resistant HBV
Patients With Undetectable Viremia, HBeAg Loss, and HBe Seroconversion at Week 24 Associated with HBsAg Loss by Week 120
Presence of Mutations Conferring Resistance to Entecavir and Lamivudine Detected in HBV-Infected Patients Before and During Treatment With Lamivudine
Correlation Between Viral Replication, Resistance, and Rebound May Explain Specific Subset of Mutations in Entecavir-Resistant HBV
Benefits of 4-5 Years of Treatment With Adefovir Sustained Following Treatment Cessation in Majority of HBeAg-Negative Patients With No Adefovir Resistance
Greater Virologic Response to Telbivudine Compared With Adefovir at 52 Weeks in HBeAg-Positive Chronic Hepatitis B Patients

Expert Analysis

Clinical Updates in HBV Treatment

Faculty:

Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
Robert G. Gish, MD
Marion G. Peters, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount clinical data on long-term therapy for the treatment of chronic hepatitis B
Describe predictors of various therapeutic endpoints in patients receiving HBV therapy
Review data regarding management strategies for patients with lamivudine resistance
Discuss the use of noninvasive fibrosis markers in inactive HBV carriers

CREDIT INFORMATION

Release Date: December 13, 2006

Expiration Date: December 12, 2007

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing contact hours

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.